JP2004534025A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004534025A5 JP2004534025A5 JP2002586930A JP2002586930A JP2004534025A5 JP 2004534025 A5 JP2004534025 A5 JP 2004534025A5 JP 2002586930 A JP2002586930 A JP 2002586930A JP 2002586930 A JP2002586930 A JP 2002586930A JP 2004534025 A5 JP2004534025 A5 JP 2004534025A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- cell
- amino acid
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 157
- 150000001875 compounds Chemical class 0.000 claims 56
- 206010028980 Neoplasm Diseases 0.000 claims 32
- 125000000539 amino acid group Chemical group 0.000 claims 32
- 210000004027 cell Anatomy 0.000 claims 31
- 150000003839 salts Chemical group 0.000 claims 21
- PCSMJKASWLYICJ-UHFFFAOYSA-N Succinic aldehyde Chemical compound O=CCCC=O PCSMJKASWLYICJ-UHFFFAOYSA-N 0.000 claims 16
- 239000003112 inhibitor Substances 0.000 claims 16
- 125000001424 substituent group Chemical group 0.000 claims 14
- ORQFDHFZSMXRLM-UHFFFAOYSA-N 4-[4-(3,4-dimethoxyphenyl)-2,3-dimethylbutyl]-1,2-dimethoxybenzene Chemical compound C1=C(OC)C(OC)=CC=C1CC(C)C(C)CC1=CC=C(OC)C(OC)=C1 ORQFDHFZSMXRLM-UHFFFAOYSA-N 0.000 claims 13
- 230000001105 regulatory effect Effects 0.000 claims 13
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 claims 11
- 230000002401 inhibitory effect Effects 0.000 claims 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims 10
- 102000000763 Survivin Human genes 0.000 claims 9
- 108010002687 Survivin Proteins 0.000 claims 9
- HCZKYJDFEPMADG-UHFFFAOYSA-N nordihydroguaiaretic acid Chemical compound C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 claims 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 8
- 241001465754 Metazoa Species 0.000 claims 8
- 230000006907 apoptotic process Effects 0.000 claims 8
- 210000004102 animal cell Anatomy 0.000 claims 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 6
- -1 dimethylaminoacetoxy Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 239000004475 Arginine Substances 0.000 claims 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 5
- 235000009697 arginine Nutrition 0.000 claims 5
- 210000005260 human cell Anatomy 0.000 claims 5
- 210000004962 mammalian cell Anatomy 0.000 claims 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 4
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 claims 4
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 claims 4
- 229940117976 5-hydroxylysine Drugs 0.000 claims 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 4
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 claims 4
- 239000004471 Glycine Substances 0.000 claims 4
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 4
- VEYYWZRYIYDQJM-ZETCQYMHSA-N N(2)-acetyl-L-lysine Chemical compound CC(=O)N[C@H](C([O-])=O)CCCC[NH3+] VEYYWZRYIYDQJM-ZETCQYMHSA-N 0.000 claims 4
- PQNASZJZHFPQLE-LURJTMIESA-N N(6)-methyl-L-lysine Chemical compound CNCCCC[C@H](N)C(O)=O PQNASZJZHFPQLE-LURJTMIESA-N 0.000 claims 4
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 claims 4
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 claims 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 4
- 239000004473 Threonine Substances 0.000 claims 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 4
- 235000004279 alanine Nutrition 0.000 claims 4
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 4
- 229960001230 asparagine Drugs 0.000 claims 4
- 235000009582 asparagine Nutrition 0.000 claims 4
- 229940009098 aspartate Drugs 0.000 claims 4
- 230000022131 cell cycle Effects 0.000 claims 4
- 235000018417 cysteine Nutrition 0.000 claims 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 4
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 claims 4
- 229950006137 dexfosfoserine Drugs 0.000 claims 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 claims 4
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 claims 4
- 229930195712 glutamate Natural products 0.000 claims 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 4
- 229960002591 hydroxyproline Drugs 0.000 claims 4
- 229960000310 isoleucine Drugs 0.000 claims 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 claims 4
- 229930182817 methionine Natural products 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 4
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims 4
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 claims 4
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 claims 4
- 230000010076 replication Effects 0.000 claims 4
- 229940034208 thyroxine Drugs 0.000 claims 4
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 claims 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 4
- 239000004474 valine Substances 0.000 claims 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 3
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 claims 3
- 101710106276 Cyclin-dependent kinase 7 Proteins 0.000 claims 3
- 102000005927 Cysteine Proteases Human genes 0.000 claims 3
- 108010005843 Cysteine Proteases Proteins 0.000 claims 3
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 3
- 239000004472 Lysine Substances 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- NTWVQPHTOUKMDI-YFKPBYRVSA-N N-Methyl-arginine Chemical compound CN[C@H](C(O)=O)CCCN=C(N)N NTWVQPHTOUKMDI-YFKPBYRVSA-N 0.000 claims 3
- 102000001253 Protein Kinase Human genes 0.000 claims 3
- 108010057085 cytokine receptors Proteins 0.000 claims 3
- 102000003675 cytokine receptors Human genes 0.000 claims 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical group P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 3
- 230000006882 induction of apoptosis Effects 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 230000003211 malignant effect Effects 0.000 claims 3
- 239000002953 phosphate buffered saline Substances 0.000 claims 3
- 108060006633 protein kinase Proteins 0.000 claims 3
- 230000004936 stimulating effect Effects 0.000 claims 3
- 210000004881 tumor cell Anatomy 0.000 claims 3
- 101150012716 CDK1 gene Proteins 0.000 claims 2
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 claims 2
- 101000868333 Homo sapiens Cyclin-dependent kinase 1 Proteins 0.000 claims 2
- 101001072338 Homo sapiens Proliferating cell nuclear antigen Proteins 0.000 claims 2
- 208000009608 Papillomavirus Infections Diseases 0.000 claims 2
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 claims 2
- 230000001640 apoptogenic effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 102000044255 human PCNA Human genes 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 229960003951 masoprocol Drugs 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 230000035897 transcription Effects 0.000 claims 2
- 238000013518 transcription Methods 0.000 claims 2
- 230000003442 weekly effect Effects 0.000 claims 2
- KJBQDYDTQCIAFO-ZLELNMGESA-N (2s)-2-amino-4-methylpentanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(C)C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O KJBQDYDTQCIAFO-ZLELNMGESA-N 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 229940126074 CDK kinase inhibitor Drugs 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 108050006400 Cyclin Proteins 0.000 claims 1
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 claims 1
- 102000010170 Death domains Human genes 0.000 claims 1
- 108050001718 Death domains Proteins 0.000 claims 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 claims 1
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 claims 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims 1
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- MXNRLFUSFKVQSK-QMMMGPOBSA-O N(6),N(6),N(6)-trimethyl-L-lysine Chemical compound C[N+](C)(C)CCCC[C@H]([NH3+])C([O-])=O MXNRLFUSFKVQSK-QMMMGPOBSA-O 0.000 claims 1
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical group CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 claims 1
- 102000008874 Ras-related protein Rap1 Human genes 0.000 claims 1
- 108050000825 Ras-related protein Rap1 Proteins 0.000 claims 1
- 206010043276 Teratoma Diseases 0.000 claims 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000032823 cell division Effects 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 150000003841 chloride salts Chemical class 0.000 claims 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims 1
- 230000002222 downregulating effect Effects 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 208000003154 papilloma Diseases 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 238000012385 systemic delivery Methods 0.000 claims 1
- 230000004565 tumor cell growth Effects 0.000 claims 1
- 0 C*C(Cc1cc(*)c(*)cc1)C(*)Cc1cc(*)c(*)cc1 Chemical compound C*C(Cc1cc(*)c(*)cc1)C(*)Cc1cc(*)c(*)cc1 0.000 description 18
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/851,425 US6608108B2 (en) | 1999-10-15 | 2001-05-09 | Method for treatment of tumors using nordihydroguaiaretic acid derivatives |
| PCT/US2002/014374 WO2002089795A1 (en) | 2001-05-09 | 2002-05-08 | Method for treatment of tumors using nordihydroguaiaretic acid derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009177106A Division JP2009242438A (ja) | 2001-05-09 | 2009-07-29 | ノルジヒドログアヤレティク酸誘導体を使用して腫瘍を処置するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004534025A JP2004534025A (ja) | 2004-11-11 |
| JP2004534025A5 true JP2004534025A5 (enExample) | 2006-01-05 |
Family
ID=25310742
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002586930A Pending JP2004534025A (ja) | 2001-05-09 | 2002-05-08 | ノルジヒドログアヤレティク酸誘導体を使用して腫瘍を処置するための方法 |
| JP2009177106A Pending JP2009242438A (ja) | 2001-05-09 | 2009-07-29 | ノルジヒドログアヤレティク酸誘導体を使用して腫瘍を処置するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009177106A Pending JP2009242438A (ja) | 2001-05-09 | 2009-07-29 | ノルジヒドログアヤレティク酸誘導体を使用して腫瘍を処置するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US6608108B2 (enExample) |
| EP (1) | EP1392293B1 (enExample) |
| JP (2) | JP2004534025A (enExample) |
| CN (1) | CN1525857B (enExample) |
| AU (1) | AU2002311890C1 (enExample) |
| CA (1) | CA2447045A1 (enExample) |
| SG (1) | SG169224A1 (enExample) |
| WO (1) | WO2002089795A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6365787B1 (en) * | 1994-09-30 | 2002-04-02 | The Johns Hopkins University | Compounds for the suppression of HIV TAT transactivation |
| US6608108B2 (en) * | 1999-10-15 | 2003-08-19 | Johns Hopkins University | Method for treatment of tumors using nordihydroguaiaretic acid derivatives |
| US7728036B2 (en) * | 2003-05-20 | 2010-06-01 | Erimos Pharmaceuticals, Llc | Methods for delivery of catecholic butanes for treatment of tumors |
| US20060141029A1 (en) * | 2003-05-20 | 2006-06-29 | Erimos Pharmaceuticals Llc | Methods and compositions for delivery of catecholic butanes for treatment of diseases |
| WO2004112695A2 (en) * | 2003-05-20 | 2004-12-29 | Erimos Pharmaceutical Llc | Methods and compositions for delivery of catecholic butanes for treatment of obesity |
| US7541344B2 (en) | 2003-06-03 | 2009-06-02 | Eli Lilly And Company | Modulation of survivin expression |
| US20060019972A1 (en) * | 2004-04-27 | 2006-01-26 | California Institute Of Technology | Methods of treating cancer by inhibiting histone gene expression |
| CN100440843C (zh) * | 2004-05-12 | 2008-12-03 | 华为技术有限公司 | 一种环网及其业务实现方法 |
| US8440648B2 (en) * | 2004-07-20 | 2013-05-14 | Erimos Pharmaceuticals Llc | Methods and compositions for treatment of intraepithelial neoplasia |
| CN101087583A (zh) * | 2004-12-22 | 2007-12-12 | 吉莱特公司 | 用生存素抑制剂来减少毛发生长 |
| AU2006208109A1 (en) * | 2005-01-27 | 2006-08-03 | Erimos Pharmaceuticals Llc | Formulations for injection of catecholic butanes, including NDGA compounds, into animals |
| CN101150955B (zh) * | 2005-01-27 | 2013-04-17 | 埃里莫斯医药品有限公司 | 递送包括ndga化合物的儿茶酚丁烷的口服制剂 |
| US20060276423A1 (en) * | 2005-04-18 | 2006-12-07 | Rachel Altura | Survivin-directed RNA interference-compositions and methods |
| US8367126B2 (en) | 2005-09-27 | 2013-02-05 | University Of Kentucky Research Foundation | Berry preparations and extracts |
| US7964223B2 (en) * | 2005-09-27 | 2011-06-21 | University Of Kentucky Research Foundation | Berry preparations and extracts |
| JP2009528294A (ja) * | 2006-02-23 | 2009-08-06 | エリモス・ファーマスーティカルズ・エルエルシー | インフルエンザウイルス感染症の治療方法 |
| US20100047371A1 (en) * | 2006-08-29 | 2010-02-25 | Mumper Russell J | Compositions and methods for oral cancer chemoprevention using berry preparations and extracts |
| EP2076252B1 (en) * | 2006-10-02 | 2014-04-02 | Erimos Pharmaceuticals LLC | Tetra-substituted ndga derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use |
| US9067875B2 (en) | 2006-10-02 | 2015-06-30 | Erimos Pharmaceuticals Llc | Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use |
| US20100093872A1 (en) * | 2008-10-15 | 2010-04-15 | Erimos Pharmaceuticals Llc | Stable aqueous formulations of water insoluble or poorly soluble drugs |
| CN101690829B (zh) * | 2009-08-31 | 2013-09-18 | 中国科学院上海硅酸盐研究所 | 一种可再细胞化的生物瓣瓣膜材料的制备方法 |
| WO2011030329A1 (en) | 2009-09-10 | 2011-03-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of treating tumors |
| CA2825894C (en) | 2011-02-02 | 2021-11-30 | Amgen Inc. | Prognosis of cancer using a circulating biomarker |
| WO2012145575A2 (en) * | 2011-04-21 | 2012-10-26 | Children's Hospital Medical Center | Therapy for leukemia |
| US10342767B2 (en) | 2011-04-21 | 2019-07-09 | Children's Hospital Medical Center | Therapy for kinase-dependent malignancies |
| US9700619B2 (en) | 2011-11-11 | 2017-07-11 | Duke University | Combination drug therapy for the treatment of solid tumors |
| US8980259B2 (en) | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
| CA2928568A1 (en) | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
| MY192978A (en) | 2015-06-22 | 2022-09-20 | Janssen Biotech Inc | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| WO2017129763A1 (en) | 2016-01-28 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer |
| MX391317B (es) | 2017-02-17 | 2025-03-21 | Promotora Tecnica Ind S A De C V | Composicion mejorada a base de acido norhidroguayaretico. |
| US12171729B2 (en) | 2019-11-25 | 2024-12-24 | The Johns Hopkins University | Formulations of terameprocol and temozolomide and their use in stimulation of humoral immunity in tumors |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5008294A (en) * | 1985-02-11 | 1991-04-16 | Chemex Pharmaceuticals, Inc. | Methods of treating tumors with compositions of catecholic butanes |
| US5276060A (en) * | 1979-06-19 | 1994-01-04 | Block/Chemex, G.P. | Methods of treating tumors with compositions of catecholic butanes |
| DE3009542A1 (de) | 1980-03-13 | 1981-09-24 | Henkel KGaA, 4000 Düsseldorf | Desodorierende kosmetische zusammensetzungen |
| US4774229A (en) * | 1982-04-05 | 1988-09-27 | Chemex Pharmaceuticals, Inc. | Modification of plant extracts from zygophyllaceae and pharmaceutical use therefor |
| US4708964A (en) * | 1984-02-09 | 1987-11-24 | Chemex Pharmaceuticals | Lipoxygenase inhibitors |
| US4880637A (en) | 1985-02-11 | 1989-11-14 | Chemex Pharmaceuticals, Inc. | Compositions of catecholic butanes with zinc |
| WO1988001509A1 (en) * | 1986-08-25 | 1988-03-10 | Chemex Pharmaceuticals, Inc. | Pharmacologically active compositions of catecholic butanes with zinc |
| US5559149A (en) | 1990-01-29 | 1996-09-24 | Johnson & Johnson Consumer Products, Inc. | Skin care compositions containing retinoids |
| US5646186A (en) | 1994-05-17 | 1997-07-08 | Johnson & Johnson Consumer Products, Inc. | Retinoid composition |
| US5409690A (en) * | 1993-06-23 | 1995-04-25 | Chemex Pharmaceuticals, Inc. | Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol |
| US6365787B1 (en) | 1994-09-30 | 2002-04-02 | The Johns Hopkins University | Compounds for the suppression of HIV TAT transactivation |
| US6071949A (en) * | 1995-03-14 | 2000-06-06 | The United States Of America As Represented By The Department Of Health And Human Services | Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents |
| US5837252A (en) | 1996-07-01 | 1998-11-17 | Larreacorp, Ltd. | Nontoxic extract of Larrea tridentata and method of making same |
| US5827898A (en) | 1996-10-07 | 1998-10-27 | Shaman Pharmaceuticals, Inc. | Use of bisphenolic compounds to treat type II diabetes |
| CA2271783C (en) * | 1996-11-20 | 2013-04-16 | Yale University | Survivin, a protein that inhibits cellular apoptosis, and its modulation |
| US6077709A (en) * | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
| US6608108B2 (en) * | 1999-10-15 | 2003-08-19 | Johns Hopkins University | Method for treatment of tumors using nordihydroguaiaretic acid derivatives |
| US6214874B1 (en) * | 1999-10-15 | 2001-04-10 | John Hopkins University | Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N |
-
2001
- 2001-05-09 US US09/851,425 patent/US6608108B2/en not_active Expired - Lifetime
-
2002
- 2002-05-08 AU AU2002311890A patent/AU2002311890C1/en not_active Ceased
- 2002-05-08 CA CA002447045A patent/CA2447045A1/en not_active Withdrawn
- 2002-05-08 CN CN028138627A patent/CN1525857B/zh not_active Expired - Lifetime
- 2002-05-08 JP JP2002586930A patent/JP2004534025A/ja active Pending
- 2002-05-08 SG SG200507965-2A patent/SG169224A1/en unknown
- 2002-05-08 EP EP02739227.3A patent/EP1392293B1/en not_active Expired - Lifetime
- 2002-05-08 WO PCT/US2002/014374 patent/WO2002089795A1/en not_active Ceased
- 2002-10-15 US US10/270,313 patent/US6777444B2/en not_active Expired - Lifetime
-
2003
- 2003-12-16 US US10/735,910 patent/US8318815B2/en not_active Expired - Fee Related
-
2009
- 2009-07-29 JP JP2009177106A patent/JP2009242438A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004534025A5 (enExample) | ||
| EP1231914B1 (en) | Nordihydroguaiaretic derivatives for use in treatment of tumors | |
| CN1525857B (zh) | 去甲二氢愈创木酸衍生物在制备治疗肿瘤的药物中的应用 | |
| CN1103219C (zh) | 含有透明质酸的制剂 | |
| CN105189438A (zh) | 用于治疗纤维化的经取代的芳族化合物及相关方法 | |
| CN101897687B (zh) | 丙戊酸钠治疗肝脏炎症相关疾病的新用途 | |
| CA2405796A1 (en) | Methods and compositions for modulating alpha adrenergic receptor activity | |
| JP2010502586A5 (enExample) | ||
| CN100409840C (zh) | GSK-3β抑制剂在制备增加骨生成的药物中的应用 | |
| US6733764B2 (en) | Immunostimulator anti-cancer compounds and methods for their use in the treatment of cancer | |
| RU2217196C2 (ru) | Способ индукции дифференцировки клеток | |
| US8927601B2 (en) | Uses of N-butylidenephthalide in treating a liver injury and improving liver function | |
| TWI311912B (en) | A pharmaceutical composition for treating cancer | |
| CN100428932C (zh) | TGF-α表达抑制剂 | |
| RU2518889C2 (ru) | Производное 5-оксипиримидина, обладающее противоопухолевой активностью | |
| CN107661324A (zh) | 普罗帕酮在制备治疗食管癌药物中的应用 | |
| WO2025119151A1 (zh) | Dr-18和单纯疱疹病毒在制备抗肿瘤药物中的应用 | |
| CN105193804A (zh) | 来那度胺在制备减轻多发性硬化症的药物中的应用 | |
| HK1062635A (en) | Method for treatment of tumors using nordihydroguaiaretic acid derivatives |